Earnings summaries and quarterly performance for Glucotrack.
Executive leadership at Glucotrack.
Board of directors at Glucotrack.
Research analysts covering Glucotrack.
Recent press releases and 8-K filings for GCTK.
Glucotrack Announces USPTO Patent Approvals for CBGM Platform
GCTK
New Projects/Investments
Product Launch
- Glucotrack, Inc. announced on January 29, 2026, that the US Patent and Trademark Office (USPTO) approved the issuance of three patents for its continuous blood glucose monitoring (CBGM) platform.
- These patents, US 12,453,494, US 12,458,257, and US 12,458,258, protect core technologies of the CBGM system, including proprietary sensor chemistry, intravascular lead design, and low-power electronics.
- The approvals are expected to strengthen Glucotrack's competitive position and intellectual property protection as the company advances its multi-year, fully implantable CBGM system toward commercialization.
Jan 29, 2026, 2:24 PM
Glucotrack, Inc. Announces Private Placement
GCTK
- Glucotrack, Inc. secured approximately $4.0 million in aggregate gross proceeds through a private placement with a single institutional investor.
- The offering included the purchase and sale of 1,033,591 shares of common stock (or equivalents) and warrants to purchase up to 2,067,182 shares of common stock.
- The effective combined price for the shares and common warrants was $3.87 per share, with the warrants having an exercise price of $3.87 per share.
- The closing of the offering occurred on December 31, 2025, and the net proceeds are expected to be used for working capital and general corporate purposes.
- The warrants will not be exercisable until receipt of shareholder approval.
Dec 31, 2025, 9:05 PM
Glucotrack Reports Q3 2025 Financial Results and Corporate Highlights
GCTK
Earnings
Debt Issuance
New Projects/Investments
- Glucotrack, Inc. reported a net loss of $4.2 million for the third quarter ended September 30, 2025, compared to a net loss of $5.1 million for the same period in 2024.
- As of September 30, 2025, the company held $7.9 million in cash and cash equivalents, which is expected to fund its operating plan through March 2026.
- The company strengthened its balance sheet by receiving $3 million in cash from a Convertible Promissory Note and establishing an equity line of credit for up to $20.0 million.
- Glucotrack plans to submit its Investigational Device Exemption (IDE) to the FDA for its novel Continuous Blood Glucose Monitor (CBGM) technology in Spring 2026.
Nov 13, 2025, 9:12 PM
GlucoTrack Special Stockholder Meeting Adjourned
GCTK
Proxy Vote Outcomes
Delisting/Listing Issues
- GlucoTrack's special meeting of stockholders, reconvened on November 7, 2025, was permanently adjourned due to the absence of a quorum.
- The meeting's purpose was to approve the issuance of common stock to Sixborough Capital Fund LP, which may represent more than 20% of the company's outstanding common stock, to comply with NASDAQ Listing Rule 5635(d).
- Only approximately 17.6% of the total votes were present or represented by proxy, indicating that a quorum was not met.
Nov 7, 2025, 5:00 PM
Glucotrack to Reconvene Special Meeting for Equity Purchase Agreement Vote
GCTK
Proxy Vote Outcomes
New Projects/Investments
- Glucotrack, Inc. (GCTK) will reconvene a Special Meeting of Shareholders on November 7, 2025, at 12 p.m. ET, to vote on an Equity Purchase Agreement.
- The agreement with Sixth Borough Capital Fund LP involves a $20 million Purchase Agreement that would allow Glucotrack to issue more than 20% of its outstanding Common Stock, in compliance with NASDAQ Listing Rule 5635(d).
- Shareholders of record as of September 23, 2025, are eligible to vote, and the Board of Directors unanimously recommends voting "FOR" all proposals.
Nov 3, 2025, 9:31 PM
Glucotrack, Inc. Schedules Special Shareholder Meeting to Vote on Equity Purchase Agreement
GCTK
Proxy Vote Outcomes
New Projects/Investments
- Glucotrack, Inc. will hold a Special Meeting of Shareholders on October 31, 2025, at 12 p.m. ET, for shareholders to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund.
- The Board of Directors unanimously recommends that shareholders vote "FOR" all proposals.
- Shareholders of record as of September 23, 2025, are entitled to vote at the Special Meeting.
Oct 28, 2025, 12:34 PM
GlucoTrack provides update on implantable CGM development and market strategy
GCTK
Product Launch
New Projects/Investments
Guidance Update
- GlucoTrack is developing a fully implantable continuous blood glucose monitor (CGM) designed to last three years and measure glucose directly in the blood, differentiating it from current wearable CGM technologies by offering no on-body wearable and overcoming lag time in critical glucose changes.
- The company completed a first-in-human OUS study safely earlier this year and is starting another OUS study in Australia in Q3 2025.
- GlucoTrack is engaged with the FDA for an Investigational Device Exemption (IDE) study in the U.S., targeting approval by the end of 2025 and trial initiation in Q1 2026.
- The total addressable market for their device is 10.7 million patients, with an estimated serviceable market of approximately 3 million patients who would likely consider an implantable CGM.
- GlucoTrack anticipates potential commercial approval in later 2028, with an estimated capital requirement of $60 million to $75 million to reach this milestone.
Sep 16, 2025, 5:30 PM
Glucotrack, Inc. secures $20.0 million equity purchase agreement
GCTK
- Glucotrack, Inc. (GCTK) entered into a Purchase Agreement with Sixth Borough Capital Fund, LP on September 11, 2025, under which the Investor committed to purchase up to $20.0 million of the Company's common stock over a 24-month period.
- The Company has the discretion to sell shares, with "Regular Purchases" limited to 20,000 shares (potentially increasing to 30,000 shares if the stock price is not less than $5.00) and the Investor's obligation per purchase capped at $500,000.
- A commitment fee of 1.5% of the total commitment amount is payable to the Investor, and the total shares sold are subject to an "Exchange Cap" of 179,792 shares (19.99% of pre-agreement outstanding shares) unless stockholder approval is obtained or certain price conditions are met.
- The agreement restricts the Company from entering into variable, reset, or adjustable equity or equity-linked transactions without Investor approval, with an exception for a future at-the-market offering facility with Dawson James Securities, Inc..
Sep 11, 2025, 8:55 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more